Recana thrombectomy catheter for treating venous obstruction and occlusion
Official title: RECANA OUS - Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-UK)
Run by Intervene, Inc. · NCT07219758 · Data updated 2026-11-12
This study will try the Recana thrombectomy catheter to open blocked or narrowed veins in adults with symptomatic post-thrombotic venous obstruction.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Intervene, Inc. Industry-sponsored |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | October 18, 2025 |
| Main results expected | July 2027 |
| Study ends | July 2027 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT07219758 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) who are ambulatory, neurologically stable, and have symptomatic chronic venous disease with flow-limiting venous outflow obstruction (CEAP C3 or greater) in the iliofemoral/IVC region are ideal candidates.
✕Probably not a fit
Patients with limited life expectancy, recent major abdominal/pelvic/peripheral vascular surgery, or other comorbidities that increase venous thromboembolism risk are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, non-randomized, single-arm study that treats eligible adults with symptomatic post-thrombotic venous inflow/outflow obstruction using the Recana Thrombectomy Catheter System. The main safety endpoint is the rate of adverse events up to 30 days after the procedure, and the primary efficacy endpoint is achieving at least 50% lumen diameter by intravascular ultrasound during the index procedure. Participants are followed with duplex ultrasound, clinical assessments, quality-of-life measures, and adverse event monitoring at 30, 90, 180, and 365 days. Enrollment is expected to take 6–9 months with total follow-up of 12 months per participant.
Why it matters
Potential benefit: If successful, the device could restore venous flow and reduce symptoms such as edema and pain in patients with post-thrombotic venous obstruction.
How similar studies have gone: Mechanical thrombectomy and other endovenous treatments have shown benefit in selected patients with venous obstruction, but this specific Recana device is being newly studied in a dedicated prospective cohort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form; 2. Participant is 18 years of age and older; 3. Neurologically stable; 4. Ambulatory; 5. Symptomatic chronic venous disease (CVD), with edema (CEAP classification of C3 or greater) or pain; 6. Flow-limiting venous outflow obstruction (\>50%) within the intended target sites, defined by (a) a common femoral vein continuous waveform without respiratory variation on duplex ultrasound, or, (b) complete occlusion of any part of the iliofemoral tract as diagnosed on baseline duplex or axial imaging per local protocol; and 7. Target treatment IVC/Common Iliac confluence to the deep veins above the knee. Exclusion Criteria: 1. Comorbidity risks which may limit longevity (\<2 years life expectancy), would preclude open surgery, or would significantly increase risk for venous thrombo-embolism (VTE); 2. Invasive abdominal, pelvic or peripheral vascular surgery within 90 days of the procedure; 3. History of stroke within the last 6 months; 4. Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period (i.e., known thrombophilia) including Heparin-induced thrombocytopenia (HIT) and antiphospholipid syndrome (APS); 5. Interventional procedure in the deep venous system (including stent placement) in the target limb or outflow vessels within 6 weeks prior to consent; 6. Acute deep venous thrombosis (DVT) in the index limb (not previously observed in the thrombus bearing segment) within 3 months prior to consent; 7. Inadequate inflow in the opinion of the investigator, that cannot be improved to the target vessel; 8. Flow-limiting venous outflow obstruction central to the target/treatment vessel that cannot be treated; 9. Pregnant and/or breastfeeding; 10. Patients with cognitive impairments who are unable to be consented; 11. Patient is enrolled in another clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results; 12. COPD or similar conditions (lung cancer, pulmonary hypertension, prior major lung surgery, emphysema, O2 dependency) that may, in the opinion of the investigator result in higher pulmonary risk; 13. Patients considered to belong to a vulnerable population; and 14. Inability to secure venous access and cross lesion.
Where it's running
-
St. Thomas' Hospital
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Stephen Black, MD — Guy's and St Thomas' NHS Foundation Trust
- Study coordinator: Clinical Affairs Team
- Email: ClinSupport@intervene-med.com
- Phone: 6509957137
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Recana thrombectomy catheter for treating venous obstruction and occlusion
This study will test whether the Recana Thrombectomy Catheter System can open blocked veins and relieve symptoms in adults with symptomatic post-thrombotic venous inflow/outflow obstruction.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.